Crafton Biotechnology

Crafton Biotechnology is a Japanese mRNA therapeutics company focused on developing next-generation vaccines and treatments using its proprietary PureCap® and CRAFT™ platforms. Founded in 2022 as a spin-off from Nagoya University and the Institute of Science Tokyo, the company specializes in high-purity, fully capped mRNA production and rapid de novo chemical synthesis without the need for DNA templates. Crafton's technology addresses industry bottlenecks such as manufacturing complexity and impurity-driven immune activation while enhancing protein expression. The company's pipeline includes programs in oncology and infectious diseases, featuring off-the-shelf cancer vaccines and a COVID-19 vaccine candidate expected to enter clinical trials in 2027.